Beyond Low-Density Lipoprotein Cholesterol. Defining the Role of Low-Density Lipoprotein Heterogeneity in Coronary Artery Disease

James Mudd, Barry A. Borlaug, Peter V. Johnston, Brian G. Kral, Rosanne Rouf, Roger S. Blumenthal, Peter O. Kwiterovich

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Recent clinical trials in patients with coronary artery disease (CAD) provide evidence that low-density lipoprotein cholesterol (LDL-C) levels should be lowered even further to prevent recurrent CAD. However, despite more aggressive interventions for lowering LDL-C levels, the majority of CAD events go undeterred, perhaps related to the fact that intervention was not started earlier in life or that LDL-C levels represent an incomplete picture of atherogenic potential. Nevertheless, LDL-C remains the contemporary standard as the primary goal for aggressive LDL reduction. If triglycerides are >200 mg/dl, the measurement of non-high-density lipoprotein cholesterol (HDL-C) is recommended. Measurement of apolipoprotein (apo)B has been shown in nearly all studies to outperform LDL-C and non-HDL-C as a predictor of CAD events and as an index of residual CAD risk. This is because apoB reflects the total number of atherogenic apoB-containing lipoproteins and is a superior predictor of the number of low-density lipoprotein particles (LDL-P). Estimates of LDL-P and size can also be made by nuclear magnetic resonance spectroscopy, density gradient ultracentrifugation, and gradient gel electrophoresis. Although a number of studies show that such estimates predict CAD, LDL-P, and size often accompany low HDL-C and high triglyceride levels, and therefore such additional lipoprotein testing has not been recommended for routine screening and follow-up. Because apoB is a superior predictor of LDL-P, we recommend that apoB and the apoB/apoA-I ratio be determined after measurement of LDL-C, non-HDL-C, and the ratio of total cholesterol/HDL-C to better predict CAD and assess efficacy of treatment.

Original languageEnglish (US)
Pages (from-to)1735-1741
Number of pages7
JournalJournal of the American College of Cardiology
Volume50
Issue number18
DOIs
StatePublished - Oct 30 2007
Externally publishedYes

Fingerprint

LDL Lipoproteins
LDL Cholesterol
Apolipoproteins B
Coronary Artery Disease
Particle Size
HDL Cholesterol
Lipoproteins
Triglycerides
Ultracentrifugation
Apolipoprotein A-I
Electrophoresis
Magnetic Resonance Spectroscopy
Gels
Cholesterol
Clinical Trials
lipoprotein cholesterol

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Beyond Low-Density Lipoprotein Cholesterol. Defining the Role of Low-Density Lipoprotein Heterogeneity in Coronary Artery Disease. / Mudd, James; Borlaug, Barry A.; Johnston, Peter V.; Kral, Brian G.; Rouf, Rosanne; Blumenthal, Roger S.; Kwiterovich, Peter O.

In: Journal of the American College of Cardiology, Vol. 50, No. 18, 30.10.2007, p. 1735-1741.

Research output: Contribution to journalArticle

Mudd, James ; Borlaug, Barry A. ; Johnston, Peter V. ; Kral, Brian G. ; Rouf, Rosanne ; Blumenthal, Roger S. ; Kwiterovich, Peter O. / Beyond Low-Density Lipoprotein Cholesterol. Defining the Role of Low-Density Lipoprotein Heterogeneity in Coronary Artery Disease. In: Journal of the American College of Cardiology. 2007 ; Vol. 50, No. 18. pp. 1735-1741.
@article{01c317d1d87d4ee1b2413043e0c92116,
title = "Beyond Low-Density Lipoprotein Cholesterol. Defining the Role of Low-Density Lipoprotein Heterogeneity in Coronary Artery Disease",
abstract = "Recent clinical trials in patients with coronary artery disease (CAD) provide evidence that low-density lipoprotein cholesterol (LDL-C) levels should be lowered even further to prevent recurrent CAD. However, despite more aggressive interventions for lowering LDL-C levels, the majority of CAD events go undeterred, perhaps related to the fact that intervention was not started earlier in life or that LDL-C levels represent an incomplete picture of atherogenic potential. Nevertheless, LDL-C remains the contemporary standard as the primary goal for aggressive LDL reduction. If triglycerides are >200 mg/dl, the measurement of non-high-density lipoprotein cholesterol (HDL-C) is recommended. Measurement of apolipoprotein (apo)B has been shown in nearly all studies to outperform LDL-C and non-HDL-C as a predictor of CAD events and as an index of residual CAD risk. This is because apoB reflects the total number of atherogenic apoB-containing lipoproteins and is a superior predictor of the number of low-density lipoprotein particles (LDL-P). Estimates of LDL-P and size can also be made by nuclear magnetic resonance spectroscopy, density gradient ultracentrifugation, and gradient gel electrophoresis. Although a number of studies show that such estimates predict CAD, LDL-P, and size often accompany low HDL-C and high triglyceride levels, and therefore such additional lipoprotein testing has not been recommended for routine screening and follow-up. Because apoB is a superior predictor of LDL-P, we recommend that apoB and the apoB/apoA-I ratio be determined after measurement of LDL-C, non-HDL-C, and the ratio of total cholesterol/HDL-C to better predict CAD and assess efficacy of treatment.",
author = "James Mudd and Borlaug, {Barry A.} and Johnston, {Peter V.} and Kral, {Brian G.} and Rosanne Rouf and Blumenthal, {Roger S.} and Kwiterovich, {Peter O.}",
year = "2007",
month = "10",
day = "30",
doi = "10.1016/j.jacc.2007.07.045",
language = "English (US)",
volume = "50",
pages = "1735--1741",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "18",

}

TY - JOUR

T1 - Beyond Low-Density Lipoprotein Cholesterol. Defining the Role of Low-Density Lipoprotein Heterogeneity in Coronary Artery Disease

AU - Mudd, James

AU - Borlaug, Barry A.

AU - Johnston, Peter V.

AU - Kral, Brian G.

AU - Rouf, Rosanne

AU - Blumenthal, Roger S.

AU - Kwiterovich, Peter O.

PY - 2007/10/30

Y1 - 2007/10/30

N2 - Recent clinical trials in patients with coronary artery disease (CAD) provide evidence that low-density lipoprotein cholesterol (LDL-C) levels should be lowered even further to prevent recurrent CAD. However, despite more aggressive interventions for lowering LDL-C levels, the majority of CAD events go undeterred, perhaps related to the fact that intervention was not started earlier in life or that LDL-C levels represent an incomplete picture of atherogenic potential. Nevertheless, LDL-C remains the contemporary standard as the primary goal for aggressive LDL reduction. If triglycerides are >200 mg/dl, the measurement of non-high-density lipoprotein cholesterol (HDL-C) is recommended. Measurement of apolipoprotein (apo)B has been shown in nearly all studies to outperform LDL-C and non-HDL-C as a predictor of CAD events and as an index of residual CAD risk. This is because apoB reflects the total number of atherogenic apoB-containing lipoproteins and is a superior predictor of the number of low-density lipoprotein particles (LDL-P). Estimates of LDL-P and size can also be made by nuclear magnetic resonance spectroscopy, density gradient ultracentrifugation, and gradient gel electrophoresis. Although a number of studies show that such estimates predict CAD, LDL-P, and size often accompany low HDL-C and high triglyceride levels, and therefore such additional lipoprotein testing has not been recommended for routine screening and follow-up. Because apoB is a superior predictor of LDL-P, we recommend that apoB and the apoB/apoA-I ratio be determined after measurement of LDL-C, non-HDL-C, and the ratio of total cholesterol/HDL-C to better predict CAD and assess efficacy of treatment.

AB - Recent clinical trials in patients with coronary artery disease (CAD) provide evidence that low-density lipoprotein cholesterol (LDL-C) levels should be lowered even further to prevent recurrent CAD. However, despite more aggressive interventions for lowering LDL-C levels, the majority of CAD events go undeterred, perhaps related to the fact that intervention was not started earlier in life or that LDL-C levels represent an incomplete picture of atherogenic potential. Nevertheless, LDL-C remains the contemporary standard as the primary goal for aggressive LDL reduction. If triglycerides are >200 mg/dl, the measurement of non-high-density lipoprotein cholesterol (HDL-C) is recommended. Measurement of apolipoprotein (apo)B has been shown in nearly all studies to outperform LDL-C and non-HDL-C as a predictor of CAD events and as an index of residual CAD risk. This is because apoB reflects the total number of atherogenic apoB-containing lipoproteins and is a superior predictor of the number of low-density lipoprotein particles (LDL-P). Estimates of LDL-P and size can also be made by nuclear magnetic resonance spectroscopy, density gradient ultracentrifugation, and gradient gel electrophoresis. Although a number of studies show that such estimates predict CAD, LDL-P, and size often accompany low HDL-C and high triglyceride levels, and therefore such additional lipoprotein testing has not been recommended for routine screening and follow-up. Because apoB is a superior predictor of LDL-P, we recommend that apoB and the apoB/apoA-I ratio be determined after measurement of LDL-C, non-HDL-C, and the ratio of total cholesterol/HDL-C to better predict CAD and assess efficacy of treatment.

UR - http://www.scopus.com/inward/record.url?scp=35349021958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35349021958&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2007.07.045

DO - 10.1016/j.jacc.2007.07.045

M3 - Article

VL - 50

SP - 1735

EP - 1741

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 18

ER -